Evaluation of Cardiovascular and Hepatic Changes in Myocardial Infarction Patients Post-Covid-19 Vaccination.

Introduction: The global COVID-19 vaccination campaign has significantly reduced severe illness and mortality; however, emerging evidence raises concerns regarding its potential cardiovascular effects, particularly myocardial infarction (MI).

Method: This study investigates the relationship between COVID-19 vaccination and MI incidence among first-time MI patients in Saudi Arabia. Post-COVID-19 vaccination within six months postvaccination accounted for potential confounding factors, such as pre-existing health conditions, age, and lifestyle. A total of 102 MI patients, with a male predominance of 60.8% and a significant correlation with middle age, were analysed. A+ blood group patients were the most prevalent (33.3%), followed by B+ (29.4%), while Rh-negative patients constituted only 7.8%. Elevated mean BNP (761.98 pg/ml), pulse rate (87.72 bpm), and systolic blood pressure (139.98 mmHg) indicated heightened cardiac stress (p < 0.01).

Results: Significant elevations in AST (121.65 U/L) and ALT (133.63 U/L) levels suggested liver stress post-Covid-19 vaccination (p < 0.01). Males had higher AST, ALT, and bilirubin levels than females, with p-values of 0.02, 0.01, and 0.04, respectively, indicating hepatic differences. Elevated biomarkers like CK-MB (58.05 IU/L) and CPK (313.86 mcg/L) further affirmed significant myocardial damage post-vaccination (p < 0.05).

Conclusion: These findings suggest a link between vaccination and cardiovascular events and highlight the importance of considering individual health profiles in evaluating vaccine safety, cardiovascular health, and hepatic implications.